Business
Cosmos Health Completes Registration Process in Germany to Commence Sales of its C-Scrub Antimicrobial Wash; Enters $750M+ Market
CHICAGO, IL / ACCESSWIRE / August 8, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global
About this update from Cosmos Health Inc.
[{"type":"text","content":"CHICAGO, IL / ACCESSWIRE / August 8, 2024 / Cosmos Health Inc. (\"Cosmos Health\" or the \"Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has completed the registration process to commence sales in Germany of its antimicrobial wash, C-Scrub Wash Chlorhexidine 4% Biocide (\"C-Scrub\").The Company anticipates shipping orders to various entities in Germany as part of its comprehensive sales strategy, targeting a diverse range of customers, including hospitals and wholesalers, while also directly reaching consumers through its online stores on platforms like Amazon.According to Markets & Data, Germany's antimicrobial market was valued at $752.76 million in 2022 and is expected to reach $1.05 billion by 2030, representing a CAGR of 4.20%.Greg Siokas, CEO of Cosmos Health, stated: \"We are excited to bring C-Scrub to the German market, a key market for us, and we look forward to expanding our presence there with both B2C and B2B strategies to capture a sizable market share.\"About C-ScrubC-Scrub, formulated with 4% chlorhexidine gluconate, provides up to 6 hours of powerful antimicrobial protection, even in the presence of biological fluids. Ideal for routine hand disinfection, it effectively targets bacteria, viruses, and fungi without fostering resistance. Gentle on the skin and iodine-free, it's an excellent choice for healthcare environments, including hospitals, clinics, and surgical suites.About Cosmos Health Inc.Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe® and C-Sept®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC ...